Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience
MetadataShow full item record
© 2018 John Wiley & Sons Ltd Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures.
Showing items related by title, author, creator and subject.
The Australian Study of HIV and Injecting Drug Use. Part 11: Predicting exposure to hepatitis C and hepatitis BCarruthers, Susan; Phillips, M.; Loxley, Wendy; Bevan, J. (1997)Researchers agree that while hepatitis B maybe in control, hepatitis C is present in epidemic proportions among injecting drug users and that current HIV prevention strategies have not been sufficient to halt the spread ...
Lenton, E.; Fraser, Suzanne (2016)Research shows that diagnosis with the blood-borne liver disease hepatitis C can lead to significant changes in intimate relationships, including a reduction in sexual contact and avoidance of new relationships. This ...
Graham, Ross; Chua, A.; Carter, K.; Delima, R.; Johnstone, D.; Herbison, C.; Firth, M.; O'Leary, R.; Milward, E.; Olynyk, J.; Trinder, D. (2010)Iron and cholesterol are both essential metabolites in mammalian systems, and too much or too little of either can have serious clinical consequences. In addition, both have been associated with steatosis and its progression, ...